Skip to main content
Equibles
KZIA logo

KZIA · Kazia Therapeutics Ltd

Track KZIA — free

Use KZIA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KZIA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$7.88 +0.03 (+0.38%)
Rebalance outlook locked
Market Cap
$122.06M
Shares
15.55M
Volume · Oct 20 168.24K Avg daily vol (3M) 278.94K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$7.88 Open$8.21 Day$7.81–8.21 52W close$5.00–16.90 Avg vol 30d282K Short int1.2M · 7.6% float · 3.8d Short vol35% DataJan 2020–Oct 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+12.1%
Trailing year
Short interest
7.6%
Latest settlement · 3.8 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 18.4 · elevated Equity put/call 0.55
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −25%
below
Price vs 50-day avg −29%
below
RSI (14) 36
neutral
MACD trend Negative
52-week position 24%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −28%
trailing
6-month return −37%
trailing
YTD return +14%
this year
Relative strength −45%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $11 › 200d $10 — 50d above 200d
Institutional flow Accumulating
3 of 35 funds reported for Sep 30 · net +62.2K sh shares · +2 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
7.55% of float · ▲ +52.6% MoM · 3.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
35 holders — near 3-yr high, broad support
Squeeze score 64
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 127%
annualized · 1-yr
Max drawdown −68%
past year
ATR 9.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−25% Bearish
Price vs 50-day avg
−29% Bearish
RSI (14)
36 Neutral
MACD trend
Negative Bearish
52-week position
24% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $11 › 200d $10 — 50d above 200d
Institutional flow Accumulating
3 of 35 funds reported for Sep 30 · net +62.2K sh shares · +2 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
7.55% of float · ▲ +52.6% MoM · 3.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
35 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $5 Now $8 · 24% Range high $17
vs 200-day avg -25% vs 50-day avg -29%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
KZIA
Kazia Therapeutics Ltd
this stock
$122.06M +14.4% — — 7.6%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.07B +13.5% +46.2% 29.9 1.8%
MRNA
Moderna, Inc.
 $90.58B +720.9% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.51B +4.6% +20.8% 19.4 2.1%
CSLLY
Csl Ltd
 $66.34B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
37
% held
26.4%
Reported
3 of 35
Top holder
Boxer Capital Management,…
Held Float
View
Held by Funds
Fund positions
3
View
Short & Settlement
Short Interest Rising
Shares short
1.2M
Days to cover
3.8d
Change
+404.7K sh
View
Short Volume
Short vol %
35%
As of
Oct 20, 2026
Short Total
View
Fails to Deliver
FTD shares
68.4K
Value
$656.3K
As of
Sep 29, 2026
View
Off-Exchange
Off-exchange %
42.4%
Week of
Sep 14, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Sep 22, 2026
This year
17
View
Exempt Offerings
Offering
$55.3M
Filed
Dec 18, 2025
View
Earnings & Events
Webcasts
Last webcast
Sep 15, 2026
View

Performance

5D 20D 120D MTD YTD
KZIA -2.0% -27.8% -36.6% -17.9% +14.4%
SPY -1.2% -0.6% +8.1% +0.8% +12.8%
vs SPY -0.8% -27.3% -44.6% -18.7% +1.6%
Key facts CIK 1075880 CUSIP 48669G303 13F (30d) 3 filings 3 filers Visit website Investor relations